$55.5 million grant has potential to enhance innovation across medical disciplines such as precision medicine, exposomics, and public health.

The Icahn School of Medicine at Mount Sinai has been awarded a five-year, $55.5 million grant from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) Program that will benefit the diverse patient population Mount Sinai serves by accelerating the development of new treatments for leading health conditions, including cardiorespiratory and psychiatric disorders, diabetes, malignancies, and infectious diseases. In particular, this award will be critical to support Mount Sinai’s ongoing response to emerging priorities such as the initial and longer term management of COVID-19.
“This grant confirms that Mount Sinai is a leader in clinical translational science nationwide. Many CTSA Programs at other leading health systems across the United States leverage unique aspects of our site, such as high performance computing, research informatics, and our exposomics infrastructure, which is beneficial for us and for the entire network,” says Rosalind J. Wright, MD, MPH, Director of ConduITS, the Horace W. Goldsmith Professor of Pediatrics at Mount Sinai Kravis Children’s Hospital, and Dean for Translational Biomedical Sciences at Icahn Mount Sinai.
“With this grant, we will be able to expand that infrastructure to, for example, continue building our integrated informatics ecosystem to facilitate big-data science across the network and enhance accessibility to data streams needed for researchers who are tackling society’s most pressing and complex health-related challenges such as health inequities, thus creating the potential to improve outcomes for all across our diverse patient populations. In this way the grant, and the science that it will facilitate, ultimately has the potential to be highly impactful in the delivery of health care. This infrastructure proved to be critical during the COVID-19 pandemic and enabled the rapid understanding of this new disease and the development of new vaccines and treatments.”